Lens anterior capsule fibrosis is considered a main pathological cause of ASC. Many studies on artificial intraocular lenses committing to reducing lens epithelial fibrosis have revealed the importance of fibrosis in the pathogenesis of ASC and PCO. TGF-β2 plays a major role in this process.
23,30 However, more potential factors involved in this pathological process need to be explored.
In the present study, we demonstrated a promoting role of H19 in the fibrotic process of lens epithelial cells. H19 was markedly overexpressed in mouse ASC models, rat lens explant EMT models and TGF-β2-induced in vitro models. Overexpression of H19 initiated and mediated the fibrotic process in HLECs. Knockdown of H19 in HLECs not only reduced mesenchymal features but also suppressed the TGF-β2-induced EMT process. Moreover, fibrotic areas were reduced after treatment with rAAV2-H19 shRNA in injury-induced ASC mouse lens anterior capsules, revealing the therapeutic potential of H19 in fibrotic cataracts.
Among the 6 lncRNAs we selected that have been demonstrated to regulate the EMT process in other diseases, only H19 was markedly upregulated in the TGF-β2-treated HLE-B3 cell line. To further verify the expression changes of H19 in fibrotic cataracts, we established a semi-in vivo EMT model and an in vivo ASC model. In the semi-in vivo model, rat lenses were explanted in M199 medium. TGF-β2 was added to the culture medium to imitate cytokine changes in the aqueous humor after cataract surgery. The expression level of H19 in the lens capsule was markedly increased after treatment for 3.5 days, which was higher than that at 7 days. This finding might be due to the promoting role of H19 occurring in the early step of EMT. Similar expression trends were also detected in renal fibrosis. In a report by Shi et al., H19 was overexpressed in 20-week-old CD-1 mice. However, the rate of increase was attenuated.
31 Similar results were also found in our ASC model. On day 3.5, H19 was highly upregulated in the injured lens capsule, and the upregulation rate slowed down in the next 3.5 days. The H19 gene is maternally imprinted and encodes the 2.3 kb H19 long noncoding RNA sharing the same locus with IGF2. Moreover, H19 is a precursor of miR-675.
32 The H19 has been reported to be involved in fibrotic processes in several organs, including cardiac fibrosis, kidney fibrosis, oral submucous fibrosis, pulmonary fibrosis, muscle fibrosis, and liver fibrosis.
31,33–38 As H19 is a highly conserved and multifunctional gene, our findings indicated that upregulation of H19 may play an important role in fibrotic diseases.
To test our hypothesis, we stably transfected HLEB-3 cell lines with lentivirus to improve H19 expression levels. The viability and migration of HLE-B3 cells were both improved after overexpression of H19. Augmentation of these two characteristics made the lens epithelial cells remaining after cataract surgery more capable of migrating to the posterior capsule and proliferating to form fibrotic plaques or forming fibrotic plaques in the anterior capsule after lens injury.
39,40 There are three kinds of EMTs that contribute to embryogenesis, fibrosis, and cancer progression.
41 The pathological factor causing fibrotic cataracts is the second kind of EMT and is irreversible.
30 In the lens epithelial fibrotic process, the cells lose epithelial characteristics and gain mesenchymal characteristics, including excessive extracellular matrix, reduced cellular adhesion, and improved motility.
42 These proteins, which are regarded as EMT biomarkers, were detected in HLEB-3 cells. When H19 was upregulated, a higher EMT level was observed. Therefore, the findings supported the hypothesis that H19 could promote fibrosis in lens epithelial cells.
Next, we further explored whether ablation of H19 could inhibit fibrosis induced by TGF-β2 in lens epithelial cells. After being cultured with TGF-β2, the HLE-B3 cell line showed increased proliferation, migration, and EMT levels, which were successfully suppressed by stable knockdown of H19. These results indicated that H19 might have therapeutic potential in fibrotic cataracts. However, in vivo, factors other than TGF-β2, such as TNF-α, are involved in the induction of fibrosis in lens epithelial cells.
43 To further investigate the therapeutic effect of H19 on lens epithelial cell fibrosis in the presence of multiple cytokines, we performed rAAV2-H19 shRNA treatment in mice with ASC. The results showed significant suppression of fibrotic plaque formation by interference with H19 in the lens capsule. In ocular diseases, there are already drugs targeting RNA approved by the US Food and Drug Administration (FDA), and an increasing number of RNA-targeted drugs are being investigated in clinical trials.
44–46 The therapeutic effect of H19 interference in the ASC mouse model provides a novel strategy for the prevention and treatment of PCO and ASC. To induce fibrosis, H19 may function through some important pathways, including the canonical Smad pathway and noncanonical pathways. In kidney fibrosis in diabetic nephropathy and pulmonary fibrosis, H19 was verified to mediate EMT via the Smad3 pathway.
31,47 The variant of H19, which lacks exon 4, promotes oral cancer by binding ZEB1 mRNA.
48 By binding hnRNPA2B1, H19 promotes colorectal cancer metastasis.
49 Moreover, by directly antagonizing P53, the tumor suppressor H19 enhances breast cancer EMT.
50
Interestingly, Lang et al.
51 reached the opposite conclusion about the functions of H19 in the lens epithelial cell fibrotic process. Instead of stable transfection, 24 hours of transient transfection of the H19 plasmid in HLECs inhibited EMT progression, revealing opposite roles of H19 in short-term upregulation versus long-term upregulation. Moreover, long-term treatment with H19 knockdown exhibited different efficacy than short-term treatment. After a month of H19 shRNA treatment in our study, the ASC mice showed shrunken fibrotic plaques of the anterior capsule. Stable transfection of H19 shRNA in HLECs exhibited EMT-inhibiting functions as well. However, in a study by Lang et al., short-term downregulation of H19 resulted in acceleration of EMT in HLECs. Shorter-term treatment, including the 24-hour upregulation of H19 in the fibrotic semi-in vivo mouse lens model and the 6-day upregulation of H19 in the fibrotic semi-in vivo human lens model in the study by Lang et al., led to inhibition of fibrotic plaque growth. A previous study has demonstrated that this may result from sponging of different microRNAs that play opposite roles in different stages of EMT progression.
29 Considering our research and Lang et al.’s research, treatment strategies targeting H19 in the earlier and later stages of lens epithelial cell fibrosis may have opposite effects, and it is better to upregulate H19 in the earlier stage and downregulate H19 in the later stage. Nevertheless, in the congenital H19 gene knockout mice in Lang et al.’s research, long-term knockout of H19 resulted in the phenotype of congenital cataract. Normal levels of H19 are essential for the normal growth and development of the lens. In addition, the application of different epithelial cell lines may have caused the conflicting results between our research and that of Lang et al.
In the field of tumor therapy, H19 has already been regarded as a novel therapeutic target.
52 Researchers consider H19 a biomarker in circulatory system disease.
53,54 However, the mechanisms underlying H19-induced HLEC fibrosis are still unclear. H19 may directly act on EMT-associated molecules instead of acting through signaling pathways. In oral submucous precancer fibrosis, H19 directly regulates one of the extracellular matrix components—COL1α.
33
In conclusion, an in vitro EMT model was used to show for the first time that H19 is highly expressed and related to EMT marker protein expression in lens epithelial cells. The rat lens explant EMT model and the ASC mouse model were used to confirm the overexpression of H19 in the fibrotic process of lens epithelial cells. Importantly, H19 promotes the proliferation, migration, and EMT of lens epithelial cells in vitro. In the presence of TGF-β2, interference with H19 repressed cytokine-induced fibrosis. The inhibitory effect of H19 shRNA on fibrotic plaque formation was confirmed in the mouse ASC model, revealing a novel therapeutic strategy for fibrotic cataracts.